10.08.2011 • NewsSymriseH1 2011sales and profits

Symrise H1 Profit Decline

Symrise reported a drop in its first-half net income to €77.4 million from €88.8 million last year. This corresponds to earnings per share of €0.65 for the recent period versus €0.75 a year earlier.

However, in the first six months of the current financial year, Symrise posted an increase in group revenues of about 2 % to €811.8 million from €797.5 million in the previous year. The sales increase was 2.6% at local currency.

The company added that during the first half, Symrise's earnings picture was mainly affected by high raw material costs and currency effects. For 2011, Symrise said it continues to target an EBITDA margin of around 20%.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.